Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling
Sign Up to like & getrecommendations! Published in 2017 at "PharmacoEconomics"
DOI: 10.1007/s40273-017-0516-2
Abstract: In the recent NICE appraisals for rheumatoid arthritis the six companies involved each independently conducted systematic reviews, economic modelling and network meta-analyses [1]. Each will have incurred substantial agency fees and internal time to manage… read more here.
Keywords: company level; level collaboration; modelling; case company ... See more keywords
The contingent nature of complementarity between results and value-based controls for managing company-level profitability: A situational strength perspective
Sign Up to like & getrecommendations! Published in 2019 at "Accounting, Organizations and Society"
DOI: 10.1016/j.aos.2019.101058
Abstract: Integrating recent theorizing on complementarity and situational strength with management control system (MCS) theory, we investigate how, why and under what circumstances companies may beneficially combine results control and two value-based controls (the use of… read more here.
Keywords: company level; situational strength; based controls; complementarity ... See more keywords
Methodology for Sustainable Resource Management Measurement at a Company Level - Case Study
Sign Up to like & getrecommendations! Published in 2017 at "Procedia Manufacturing"
DOI: 10.1016/j.promfg.2017.07.173
Abstract: Abstract The greatest challenge is to translate the theoretical goal of sustainable development into practical usage at different levels of application, including the company level. Sustainability should be managed, what requires appropriate measurement. Consequently, authors… read more here.
Keywords: sustainable resource; company level; methodology; company ... See more keywords
Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Health Policy and Management"
DOI: 10.34172/ijhpm.2022.6575
Abstract: Background: Creating new therapies often involves drug companies paying healthcare professionals and institutions for research and development (R&D) activities, including clinical trials. However, industry sponsorship can create conflicts of interest (COIs). We analysed approaches to… read more here.
Keywords: country; company level; company; disclosure ... See more keywords